Choose Your Country or Region

Anti-PAI1 Rabbit Antibody [E17P19]

Catalog No.: F3786

Application: Reactivity: Mouse, Rat, Human

Usage Information

Dilution
WB1:1000 IP1:30 IF1:10000 FCM1:60

Application
WB, IP, IF, FCM

Reactivity
Mouse, Rat, Human

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
45 kDa 45 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Positive Control	Human liver lysate; Mouse placenta; Rat placenta; Human placenta; Mouse liver tissue; Rat lung tissue; HepG2; Hepa1-6; HUVEC
Negative Control	HEK293; NIH/3T3

Datasheet & SDS

Biological Description

Specificity
PAI1 Rabbit mAb detects endogenous levels of total PAI1 protein.

Clone
E17P19

Synonym(s)
PAI1, PLANH1, SERPINE1, Plasminogen activator inhibitor 1, PAI, PAI-1, Endothelial plasminogen activator inhibitor, Serpin E1

Background
Plasminogen Activator Inhibitor-1 (PAI-1), also known as serpin E1, is a major serine protease inhibitor encoded by the SERPINE1 gene on chromosome 7 and serves as the main physiological blocker of tissue-type (tPA) and urokinase-type (uPA) plasminogen activators, which convert plasminogen to plasmin in fibrinolysis. This 379‑amino‑acid glycoprotein (~48 kDa) has a conserved serpin fold of three β‑sheets, nine α‑helices, and a reactive center loop (RCL) with residues Arg346 and Met347 essential for protease recognition and irreversible inhibition. In its active state, PAI‑1 is metastable and can spontaneously shift to an inactive latent form unless stabilized by vitronectin. It also influences extracellular matrix remodeling, cell adhesion, migration, angiogenesis, and inflammation, and is produced by endothelial cells, hepatocytes, adipocytes, and some neurons. High PAI‑1 levels are linked to thrombosis, fibrosis, obesity, insulin resistance, cancers, vascular stiffness, and senescence, and in the CNS it affects neuroinflammation and amyloid‑β clearance, relating to Alzheimer’s and Parkinson’s disease. As an acute‑phase reactant, its rise during injury or infection can become harmful if chronically elevated, and genetic variations in SERPINE1 affect its expression and disease risk.

Background

Plasminogen Activator Inhibitor-1 (PAI-1), also known as serpin E1, is a major serine protease inhibitor encoded by the SERPINE1 gene on chromosome 7 and serves as the main physiological blocker of tissue-type (tPA) and urokinase-type (uPA) plasminogen activators, which convert plasminogen to plasmin in fibrinolysis. This 379‑amino‑acid glycoprotein (~48 kDa) has a conserved serpin fold of three β‑sheets, nine α‑helices, and a reactive center loop (RCL) with residues Arg346 and Met347 essential for protease recognition and irreversible inhibition. In its active state, PAI‑1 is metastable and can spontaneously shift to an inactive latent form unless stabilized by vitronectin. It also influences extracellular matrix remodeling, cell adhesion, migration, angiogenesis, and inflammation, and is produced by endothelial cells, hepatocytes, adipocytes, and some neurons. High PAI‑1 levels are linked to thrombosis, fibrosis, obesity, insulin resistance, cancers, vascular stiffness, and senescence, and in the CNS it affects neuroinflammation and amyloid‑β clearance, relating to Alzheimer’s and Parkinson’s disease. As an acute‑phase reactant, its rise during injury or infection can become harmful if chronically elevated, and genetic variations in SERPINE1 affect its expression and disease risk.

References
https://pubmed.ncbi.nlm.nih.gov/33415130/ https://pubmed.ncbi.nlm.nih.gov/20626406/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%